Lassa fever is a zoonotic disease caused by the Lassa virus, a rodent-borne arenavirus endemic to West Africa. Recent steady increase in reported cases of the disease in Nigeria, where 123 deaths occurred in 546 confirmed cases in 2019 has further underlined the need to accelerate the development of vaccines for preventing the disease. Intensified research and development of Lassa fever medical countermeasures have yielded some vaccine candidates with preclinical scientific plausibility using predominantly novel technology. The more advanced candidates are based on recombinant measles, Vesicular Stomatitis Virus or Mopiea and Lassa virus reassortants expressing Lassa virus antigens, and the deoxyribonucleic acid platform. However, the Lassa fever portfolio still lags behind other neglected tropical diseases’, and further investments are needed for continued development and additional research, such as the safety and efficacy of these vaccine candidates in special populations.

拉沙热是由拉沙病毒引起的人畜共患病，拉沙病毒是一种西非地方性的啮齿动物传播的沙粒病毒。尼日利亚最近报告的该病病例稳步增加，2019 年 546 例确诊病例中有 123 人死亡，这进一步强调了加快开发预防该疾病的疫苗的必要性。拉沙热医学对策的强化研究和开发已经产生了一些具有临床前科学合理性的候选疫苗，这些候选疫苗主要使用新技术。更先进的候选药物基于表达拉沙病毒抗原的重组麻疹、水疱性口炎病毒或 Mopiea 和拉沙病毒重配体，以及脱氧核糖核酸平台。然而，拉沙热组合仍然落后于其他被忽视的热带病'，